CA2557615A1 - Traitement du choc hemorragique au moyen d'inhibiteurs du recepteur 5a complementaires - Google Patents

Traitement du choc hemorragique au moyen d'inhibiteurs du recepteur 5a complementaires Download PDF

Info

Publication number
CA2557615A1
CA2557615A1 CA002557615A CA2557615A CA2557615A1 CA 2557615 A1 CA2557615 A1 CA 2557615A1 CA 002557615 A CA002557615 A CA 002557615A CA 2557615 A CA2557615 A CA 2557615A CA 2557615 A1 CA2557615 A1 CA 2557615A1
Authority
CA
Canada
Prior art keywords
side chain
shock
inhibitor
group
haemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002557615A
Other languages
English (en)
Inventor
Denis W. Harkin
Thomas F. Lindsay
Steven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CA2557615A1 publication Critical patent/CA2557615A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002557615A 2003-05-15 2004-05-14 Traitement du choc hemorragique au moyen d'inhibiteurs du recepteur 5a complementaires Abandoned CA2557615A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003902354A AU2003902354A0 (en) 2003-05-15 2003-05-15 Treatment of haemorrhagic shock
AU2003902354 2003-05-15
PCT/AU2004/000642 WO2004100975A1 (fr) 2003-05-15 2004-05-14 Traitement du choc hemorragique au moyen d'inhibiteurs du recepteur 5a complementaires

Publications (1)

Publication Number Publication Date
CA2557615A1 true CA2557615A1 (fr) 2004-11-25

Family

ID=31501223

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002557615A Abandoned CA2557615A1 (fr) 2003-05-15 2004-05-14 Traitement du choc hemorragique au moyen d'inhibiteurs du recepteur 5a complementaires

Country Status (5)

Country Link
EP (1) EP1635857A1 (fr)
JP (1) JP2006528208A (fr)
AU (1) AU2003902354A0 (fr)
CA (1) CA2557615A1 (fr)
WO (1) WO2004100975A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3078658T (pt) 2008-12-22 2019-07-16 Chemocentryx Inc Antagonistas do c5ar
ES2632975T3 (es) 2010-06-24 2017-09-18 Chemocentryx, Inc. Antagonistas de C5aR
PL3200791T3 (pl) 2014-09-29 2020-08-10 Chemocentryx, Inc. Sposoby i produkty pośrednie w otrzymywaniu antagonistów C5AR
CN108601790A (zh) 2016-01-14 2018-09-28 凯莫森特里克斯股份有限公司 C3肾小球病的治疗方法
KR102395093B1 (ko) 2016-04-04 2022-05-04 케모센트릭스, 인크. 가용성 C5aR 길항제
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
KR102586710B1 (ko) 2017-05-31 2023-10-10 케모센트릭스, 인크. C5a 억제제로서의 5-5 융합 고리
US20190144389A1 (en) 2017-10-30 2019-05-16 Chemocentryx, Inc. Deuterated compounds as immunomodulators
EP3728202A4 (fr) 2017-12-22 2021-05-26 ChemoCentryx, Inc. Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
EP3728203B1 (fr) 2017-12-22 2024-03-13 ChemoCentryx, Inc. COMPOSÉS CYCLIQUES CONDENSÉS 6,5 À SUBSTITUTION DIARYLE, UTILISÉS EN TANT QU'INHIBITEURS DU C5aR
US20190300526A1 (en) 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist

Also Published As

Publication number Publication date
WO2004100975A1 (fr) 2004-11-25
AU2003902354A0 (en) 2003-05-29
EP1635857A1 (fr) 2006-03-22
JP2006528208A (ja) 2006-12-14

Similar Documents

Publication Publication Date Title
KR100483779B1 (ko) 지혈성디펩티드를포함하는약학조성물
AU2021202310A1 (en) Compositions and methods for treating acute radiation syndrome
US20220160820A1 (en) Modulators of complement activity
US20180296632A1 (en) Use of peptides to stimulate the immune system
US20100267639A1 (en) Treatment of osteoarthritis
CA2557615A1 (fr) Traitement du choc hemorragique au moyen d'inhibiteurs du recepteur 5a complementaires
US5498601A (en) Platelet aggregation-inhibiting peptides
RU2313364C2 (ru) Способы индукции длительного иммунного ответа
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
RU2545718C2 (ru) Лечение сосудистых осложнений диабета
WO2015022326A1 (fr) Peptides en tant qu'agents actifs pour le traitement d'un dysfonctionnement du greffon primaire
KR100186656B1 (ko) 신규한 펩타이드, 및 전기 펩타이드를 이용하는 혈소판 응집저해제, 체외순환하는 혈액의 혈액응고 저해제, 세포점착저해제, 종양전이 저해제, 수혈용 혈소판 제제의 보호제, 수혈용 혈소판 제제 및 혈소판 제제 팩
US20060276390A1 (en) Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
AU2004238089A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
EP1551950A2 (fr) Protection en cas de transplantation d'organe par des peptides d'hormone stimulaant l'alpha-melanocyte
KR100266929B1 (ko) 약학적 라이신-함유 폴리펩티드 조성물 및 그의 사용방법
AU2018210166A1 (en) Compositions and methods for treating iron overload
US20070054841A1 (en) Method of treatment of systemic injury secondary to burns
US20100099602A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
US20210228681A1 (en) Compositions and methods for treating glioblastoma
ES2366538T3 (es) Tratamiento de la enfermedad inflamatoria intestinal.
WO2022177635A2 (fr) Compositions et méthodes pour le traitement de maladies microbiennes
WO2011093851A1 (fr) Procédé de traitement de l'hyperperméabilité vasculaire
AU2004241673A1 (en) Method of treatment of systemic injury secondary to burns
MCPHADEN et al. THE COMPLEMENT SYSTEM Introduction The complement system comprises a group of about 20 distinct plasma proteins which have a key role to play in host defence against infection and in helping to mediate inflammation.

Legal Events

Date Code Title Description
FZDE Discontinued